Life Biosciences will test its gene therapy designed to partially reset a cell’s age and potentially reverse vision loss in ...
The U.S. Food and Drug Administration (FDA) has approved a drug to control seizures in dogs with idiopathic epilepsy, a type ...
There's been a small but "alarming" bump in aortic stenosis (AS) deaths among people ages 45 to 74 in recent years, according ...
The FDA approved a larger nelarabine vial to improve dosing flexibility and simplify treatment for adult and pediatric ...
The FDA has approved a label update for an inhaled insulin indicated for adults with type 1 or type 2 diabetes, according to ...
The FDA approved a fixed-dose combination of carbachol and brimonidine tartrate for presbyopia, offering a noninvasive ...
A new drug application (NDA) has been submitted to the FDA seeking approval of lirafugratinib (RLY-4008), a selective FGFR2 ...
The FDA approved Darzalex Faspro with Velcade, Revlimid and dexamethasone for newly diagnosed multiple myeloma ineligible for ...
The FDA approved re-administration of iDose TR for patients with healthy corneas, enhancing treatment flexibility for ...
Guardant Health (GH) is back in focus after the FDA approved its Guardant360 CDx liquid biopsy as a companion diagnostic for BRAF V600E-mutant metastatic colorectal cancer and the company announced a ...
GlobalData on MSN
Life Bio receives FDA approval for ER-100 clinical trial
The Phase I trial will recruit participants who have been diagnosed with non-arteritic anterior ischaemic optic neuropathy and open-angle glaucoma.
FDA approves KBroVet chewable tablets for managing canine idiopathic epilepsy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results